(VIANEWS) – Antero Resources (AR), Deere & Company (DE), Neurocrine Biosciences (NBIX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Antero Resources (AR)
115.8% sales growth and 37.74% return on equity
Antero Resources Corporation, an independent oil and natural gas company, acquires, explores for, develops, and produces natural gas, natural gas liquids, and oil properties in the United States. As of December 31, 2021, it had approximately 502,000 net acres in the Appalachian Basin; and 174,000 net acres in the Upper Devonian Shale. The company also owned and operated 494 miles of gas gathering pipelines in the Appalachian Basin; and 21 compressor stations. It had estimated proved reserves of 17.7 trillion cubic feet of natural gas equivalent, including 10.2 trillion cubic feet of natural gas; 718 million barrels of assumed recovered ethane; 501 million barrels of primarily propane, isobutane, normal butane, and natural gasoline; and 36 million barrels of oil. The company was formerly known as Antero Resources Appalachian Corporation and changed its name to Antero Resources Corporation in June 2013. Antero Resources Corporation was founded in 2002 and is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, Antero Resources has a trailing twelve months EPS of $5.94.
PE Ratio
Antero Resources has a trailing twelve months price to earnings ratio of 4.05. Meaning, the purchaser of the share is investing $4.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.74%.
Sales Growth
Antero Resources’s sales growth is negative 33.5% for the present quarter and 115.8% for the next.
2. Deere & Company (DE)
21.1% sales growth and 36.76% return on equity
Deere & Company manufactures and distributes various equipment worldwide. The company operates through four segments: Production and Precision Agriculture, Small Agriculture and Turf, Construction and Forestry, and Financial Services. The Production and Precision Agriculture segment provides mid-size tractors, combines, cotton pickers and strippers, sugarcane harvesters, harvesting front-end equipment, sugarcane loaders, pull-behind scrapers, and tillage and seeding equipment, as well as application equipment, including sprayers and nutrient management, and soil preparation machinery for grain growers. The Small Agriculture and Turf segment offers utility tractors, and related loaders and attachments; turf and utility equipment, including riding lawn equipment, commercial mowing equipment, golf course equipment, and utility vehicles, as well as implements for mowing, tilling, snow and debris handling, aerating, residential, commercial, golf, and sports turf care applications; other outdoor power products; and hay and forage equipment. This segment also resells products from other manufacturers. It serves dairy and livestock producers, crop producers, and turf and utility customers. The Construction and Forestry segment provides a range of backhoe loaders, crawler dozers and loaders, four-wheel-drive loaders, excavators, motor graders, articulated dump trucks, landscape and skid-steer loaders, milling machines, pavers, compactors, rollers, crushers, screens, asphalt plants, log skidders, log feller bunchers, log loaders and forwarders, log harvesters, and attachments; and roadbuilding equipment. The Financial Services segment finances sales and leases agriculture and turf, and construction and forestry equipment. It also offers wholesale financing to dealers of the foregoing equipment; and extended equipment warranties, as well as finances retail revolving charge accounts. Deere & Company was founded in 1837 and is headquartered in Moline, Illinois.
Earnings Per Share
As for profitability, Deere & Company has a trailing twelve months EPS of $26.9.
PE Ratio
Deere & Company has a trailing twelve months price to earnings ratio of 14.24. Meaning, the purchaser of the share is investing $14.24 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.76%.
Moving Average
Deere & Company’s value is below its 50-day moving average of $413.55 and above its 200-day moving average of $381.67.
Yearly Top and Bottom Value
Deere & Company’s stock is valued at $383.04 at 11:22 EST, way under its 52-week high of $448.40 and way above its 52-week low of $283.81.
Volume
Today’s last reported volume for Deere & Company is 382086 which is 76.53% below its average volume of 1628630.
3. Neurocrine Biosciences (NBIX)
17.6% sales growth and 10.03% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $4.16.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 24.13. Meaning, the purchaser of the share is investing $24.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 32.1%, now sitting on 1.49B for the twelve trailing months.
Yearly Top and Bottom Value
Neurocrine Biosciences’s stock is valued at $100.38 at 11:22 EST, way below its 52-week high of $129.29 and way above its 52-week low of $75.25.
Moving Average
Neurocrine Biosciences’s value is below its 50-day moving average of $101.61 and below its 200-day moving average of $106.92.
Volume
Today’s last reported volume for Neurocrine Biosciences is 482489 which is 42.05% below its average volume of 832685.
4. STAAR Surgical Company (STAA)
14.6% sales growth and 13.12% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.76.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 81.3. Meaning, the purchaser of the share is investing $81.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.12%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 284.39M for the twelve trailing months.
5. HireQuest (HQI)
12.6% sales growth and 22.81% return on equity
HireQuest, Inc. provides on-demand and temporary staffing solutions in the United States. The company provides temporary staffing services, including skilled and semi-skilled labor and industrial personnel, clerical and administrative personnel, and construction personnel. As of March 25, 2021, the company had a network of approximately 139 franchisee-owned offices in 35 states and the District of Columbia. It serves customers primarily in the construction, industrial/manufacturing, warehousing, hospitality, recycling/waste management, disaster recovery, logistics, auctioneering, landscaping, and retail industries. The company was formerly known as Command Center, Inc. and changed its name to HireQuest, Inc. in September 2019. HireQuest, Inc. was founded in 2002 and is headquartered in Goose Creek, South Carolina.
Earnings Per Share
As for profitability, HireQuest has a trailing twelve months EPS of $0.86.
PE Ratio
HireQuest has a trailing twelve months price to earnings ratio of 24.49. Meaning, the purchaser of the share is investing $24.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.81%.
